Trial Profile

A phase 2b trial of UB-311

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UB 311 (Primary)
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use
Sponsors United Biomedical

Most Recent Events

24 Mar 2022 According to a Vaxxinity media release, this trial is expected to begin in the late 2022
30 Dec 2021 New trial record
23 Dec 2021 According to a Vaxxinity media release, this trial is expected to begin in the second half of 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com